Home › Entities › academia › Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Research article (Molecular Oncology, 2016) · cited 28× · AI/ML
academia openalex:W2397361343
Press Enter · cited answer in seconds

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Summary

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients is a scholarly article[1].

Key Facts

  • Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients's instance of is recorded as scholarly article[2].

Related Entities

Ole Winther

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. Retrieved May 24, 2026, from https://4ort.xyz/entity/angiotensinogen-and-hla-class-ii-predict-bevacizumab-response-in-recurrent-glioblastoma-patients
MLA “Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/angiotensinogen-and-hla-class-ii-predict-bevacizumab-response-in-recurrent-glioblastoma-patients.
BibTeX @misc{4ortxyz_angiotensinogen-and-hla-class-ii-predict-bevacizumab-response-in-recurrent-glioblastoma-patients_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients}}, year = {2026}, url = {https://4ort.xyz/entity/angiotensinogen-and-hla-class-ii-predict-bevacizumab-response-in-recurrent-glioblastoma-patients}, note = {Accessed: 2026-05-24}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients — https://4ort.xyz/entity/angiotensinogen-and-hla-class-ii-predict-bevacizumab-response-in-recurrent-glioblastoma-patients (retrieved 2026-05-24)

Canonical URL: https://4ort.xyz/entity/angiotensinogen-and-hla-class-ii-predict-bevacizumab-response-in-recurrent-glioblastoma-patients · Last refreshed: